We wanted to share this article that we found published by the New England Journal of Medicine. We all have a lot of ongoing questions about the ongoing COVID-19 pandemic, and this is a great resource that answers nearly every question we’ve had regarding testing, vaccines and more.

Covid-19 Vaccine — Frequently Asked Questions


Image courtesy of NEJM

A collection of resources on Covid-19 vaccines, including frequently asked questions, continuing medical education, published research, and commentary.

CORONAVIRUS (COVID-19) VACCINE RESOURCES VACCINE FAQ

Frequently Asked Questions

Click the screen shot below to see the full article on the NEJM website:

nejm cv faqs

Paul E. Sax, M.D.

Paul Sax, M.D., a Professor of Medicine at Harvard Medical School and an infectious disease specialist, provides concise and engaging answers to clinicians’ questions about Covid-19 vaccination and to the questions and concerns patients will raise.

NEJM Journal Watch Infectious Diseases

About the NEJM Journal Watch Infectious Diseases Board

Paul E. Sax, MD, is Clinical Director of the Division of Infectious Diseases at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. He is actively involved in HIV research, clinical practice, and teaching. His research interests include clinical trials of new antiretroviral therapies, the cost-effectiveness of HIV management strategies, and the complications of antiretroviral treatment. Dr. Sax is Principal Investigator of the Brigham and Women’s Hospital AIDS Clinical Trials Unit and a member of the Cost Effectiveness of Preventing AIDS Complications (CEPAC) Research Group. He was Editor-in-Chief of NEJM Journal Watch AIDS Clinical Care from 2003 to 2014 and currently writes the HIV and ID Observations blog for NEJM Journal Watch. Dr. Sax is Editor-in-Chief of Open Forum Infectious Diseases and HIV Section Editor for UpToDate.

Disclosures

Consultant / Advisory board - 

Gilead Sciences; GlaxoSmithKline/ViiV; Janssen; Merck

Grant/ Research Support - 

NIH; Gilead Sciences; GlaxoSmithKline/ViiV

Editorial Boards - 

UpToDate; Open Forum Infectious Diseases